- Home
- FRAF vs CRBP Comparison
FRAF vs CRBP Comparison
Compare FRAF & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FRAF | CRBP |
|---|---|---|
| Founded | 1906 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 206.3M | 202.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | FRAF | CRBP |
|---|---|---|
| Price | $52.91 | $10.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $50.29 |
| AVG Volume (30 Days) | 37.8K | ★ 268.0K |
| Earning Date | 01-27-2026 | 11-12-2025 |
| Dividend Yield | ★ 2.47% | N/A |
| EPS Growth | ★ 9.43 | N/A |
| EPS | ★ 3.50 | N/A |
| Revenue | ★ $77,783,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $100.00 |
| P/E Ratio | $15.23 | ★ N/A |
| Revenue Growth | ★ 8.75 | N/A |
| 52 Week Low | $28.01 | $4.64 |
| 52 Week High | $54.72 | $20.56 |
Technical Indicators
Market Signals| Indicator | FRAF | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 67.49 | 34.96 |
| Support Level | $52.04 | $10.10 |
| Resistance Level | $54.72 | $10.82 |
| Average True Range (ATR) | 1.19 | 0.64 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 77.83 | 4.65 |
Price Performance
Historical ComparisonAbout FRAF Franklin Financial Services Corporation
Franklin Financial Services Corp is a bank holding company based in the United States. It is engaged in general commercial, retail banking and trust services normally associated with community banks. It offers a broad range of banking services to businesses, individuals and governmental entities which includes accepting and maintaining cheques, savings, and time deposit accounts, providing investment and trust services, making loans and providing safe deposit facilities. The bank also performs personal, corporate, pension and fiduciary services through its Investment and Trust Services Department.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.